BR112015030211A2 - Vetores lentivirais contendo uma sequência promotora a montante da mhc de classe i, mhc de classe ii ou microglobulina beta-2 - Google Patents

Vetores lentivirais contendo uma sequência promotora a montante da mhc de classe i, mhc de classe ii ou microglobulina beta-2

Info

Publication number
BR112015030211A2
BR112015030211A2 BR112015030211A BR112015030211A BR112015030211A2 BR 112015030211 A2 BR112015030211 A2 BR 112015030211A2 BR 112015030211 A BR112015030211 A BR 112015030211A BR 112015030211 A BR112015030211 A BR 112015030211A BR 112015030211 A2 BR112015030211 A2 BR 112015030211A2
Authority
BR
Brazil
Prior art keywords
mhc
class
beta
microglobulin
promoter sequence
Prior art date
Application number
BR112015030211A
Other languages
English (en)
Inventor
Sarry Emeline
Bauche Cécile
Original Assignee
Theravectys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravectys filed Critical Theravectys
Publication of BR112015030211A2 publication Critical patent/BR112015030211A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

VETORES LENTIVIRAIS CONTENDO UMA SEQUÊNCIA PROMOTORA A MONTANTE DA MHC DE CLASSE I, MHC DE CLASSE II OU MICROGLOBULINA BETA-2. A presente invenção se refere à inserção de uma sequência promotora a montante da MHC de classe I, MHC de Classe II, ou microglobulina- (Beta)2 em um vetor lentiviral para aumentar os títulos virais. A invenção abrange estes vetores, métodos para produzir os vetores e métodos para a sua utilização, incluindo utilizações medicinais
BR112015030211A 2013-06-03 2014-05-23 Vetores lentivirais contendo uma sequência promotora a montante da mhc de classe i, mhc de classe ii ou microglobulina beta-2 BR112015030211A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305738 2013-06-03
PCT/EP2014/060740 WO2014195159A1 (en) 2013-06-03 2014-05-23 Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence

Publications (1)

Publication Number Publication Date
BR112015030211A2 true BR112015030211A2 (pt) 2017-08-22

Family

ID=48578998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030211A BR112015030211A2 (pt) 2013-06-03 2014-05-23 Vetores lentivirais contendo uma sequência promotora a montante da mhc de classe i, mhc de classe ii ou microglobulina beta-2

Country Status (10)

Country Link
US (1) US9657311B2 (pt)
EP (1) EP3004361A1 (pt)
JP (1) JP2016520316A (pt)
KR (1) KR20160011645A (pt)
CN (1) CN105683383B (pt)
AU (1) AU2014277092B2 (pt)
BR (1) BR112015030211A2 (pt)
CA (1) CA2913854A1 (pt)
SG (1) SG11201509743WA (pt)
WO (1) WO2014195159A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2874501T3 (es) * 2013-10-18 2021-11-05 Taiho Pharmaceutical Co Ltd Animal no humano que expresa HLA de clase I
WO2016120489A2 (en) * 2015-02-01 2016-08-04 Theravectys Lentiviral vectors for expression of mycobacterium tuberculosis antigens
IL279520B2 (en) 2016-01-15 2023-03-01 American Gene Tech Int Inc Methods and preparations for the activation of gamma-delta t cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US20200080107A1 (en) * 2018-09-07 2020-03-12 Crispr Therapeutics Ag Universal donor cells
IT202100011576A1 (it) * 2021-05-06 2022-11-06 Univ Degli Studi Padova Nuova sequenza promotore per terapia genica

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007404A1 (en) * 1995-08-21 1997-02-27 THE GOVERMENT OF THE UNITED STATES OF AMERICA reprsented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods of assessing mhc class i expression and proteins capable of modulating class i expression
US20070037165A1 (en) * 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
JP2007068473A (ja) * 2005-09-07 2007-03-22 Yokohama City Univ Ｍｈｃ遺伝子の転写因子結合配列を含む発現ベクター
MX342449B (es) * 2007-08-03 2016-09-29 Pasteur Institut Vectores de transferencia de gen lentiviral y sus aplicaciones medicinales.
EP2385107B1 (en) * 2010-05-03 2016-08-24 Institut Pasteur Lentiviral vector based immunological compounds against malaria
EP2666477A1 (en) * 2012-05-23 2013-11-27 Theravectys Lentiviral vectors containing an MHC class I promoter
CA2833173C (en) * 2011-04-20 2023-09-05 University Of Washington Through Its Center For Commercialization Beta-2 microglobulin-deficient cells
CA2849652C (en) * 2011-09-26 2017-11-21 Theravectys Use of non-subtype b gag proteins for lentiviral packaging
WO2015063708A1 (en) * 2013-10-31 2015-05-07 Theravectys LENTIVIRAL VECTORS FOR INDUCING CD4+ and CD8+ IMMUNE RESPONSES IN VACCINATION OF HUMANS INFECTED WITH HIV-1

Also Published As

Publication number Publication date
AU2014277092A1 (en) 2015-12-10
CA2913854A1 (en) 2014-12-11
JP2016520316A (ja) 2016-07-14
CN105683383B (zh) 2020-08-21
AU2014277092B2 (en) 2019-04-04
KR20160011645A (ko) 2016-02-01
EP3004361A1 (en) 2016-04-13
CN105683383A (zh) 2016-06-15
WO2014195159A1 (en) 2014-12-11
US9657311B2 (en) 2017-05-23
SG11201509743WA (en) 2015-12-30
US20140356946A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
BR112015030211A2 (pt) Vetores lentivirais contendo uma sequência promotora a montante da mhc de classe i, mhc de classe ii ou microglobulina beta-2
EP4295808A3 (en) Teeth repositioning system and method of producing the same
PH12018500571A1 (en) Hepatitis b core protein modulators
PH12016501762A1 (en) Hepatitis b core protein allosteric modulators
BR112016012358A2 (pt) peptídios terapêuticos
MX2016012845A (es) Vacuna contra el virus de la diarrea epidemica porcina.
BR112016030670A2 (pt) "imunocitoquina"
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
BR112016029914A2 (pt) dispositivos dilatadores nasais
EA201692205A1 (ru) Механическая система фиксации для строительных панелей
BR112016015629A2 (pt) produção de vetores virais adenoassociados de alto título
BR112013004288A2 (pt) formas galênicas de múltiplos epítopos direcionados para indução de uma resposta imunológica a antigênios.
BR112019022321A2 (pt) Tcr e peptídeos
EA201891459A1 (ru) Новое поколение антигенспецифических tcr
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
BR112019005516A2 (pt) novo sítio de inserção do ehv orf70
BR112019008781A2 (pt) poxvírus quiméricos sintéticos
BR112021014944A2 (pt) Toxinas apxia, apxiia e apxiiia inativas
BR112017014598A2 (pt) métodos e usos para hidrólise de queratina
BR112021019120A2 (pt) Células t específicas para antígenos de múltiplos vírus respiratórios e métodos de produção e uso das mesmas terapeuticamente
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
BR112017002173A2 (pt) anticorpos semelhantes à angiopoietina e métodos de uso
BR112019005418A2 (pt) novos promotores
MY189501A (en) Pestivirus vaccines for congenital tremors
MX2019007924A (es) Vacunas contra la influenza.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2622 DE 06-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.